SOURCE: Pharming Group N.V.

October 12, 2006 12:17 ET

PHARMING'S EXTRAORDINARY MEETING OF SHAREHOLDERS TO BE HELD IN LEIDEN ON NOVEMBER 1, 2006

LEIDEN, THE NETHERLANDS -- (MARKET WIRE) -- October 12, 2006 -- Biotech company Pharming Group NV ("Pharming") (Euronext: PHARM) (PHARM.AS) announced today that the Company's next Extraordinary Meeting of shareholders will be held at the Holiday Inn in Leiden on November 1, 2006 commencing at 11.00 am CET. Purpose of the meeting is to vote on the proposal to appoint Dr. Bruno Giannetti as a member of the Board of Management in the position of Chief Operations Officer.

Dr. Giannetti (54) has more than 25 years experience in the pharmaceutical and biotech industry. He was Head of Clinical Research at Madaus, Germany and world-wide Vice-President Marketing and Medical Information at Immuno, Austria. He served as senior management consultant for pharmaceutical R&D projects at Coopers & Lybrand, Switzerland and UK and as Chief Operations Officer and subsequently President and CEO of Verigen AG, Germany. He is currently the CEO of AM-Pharma, The Netherlands.

Dr. Giannetti is the founder of CRM, a well established European Clinical Research Organization specialized in international pharmaceutical clinical research. He is a visiting lecturer at the University of Bonn and former President of the Biotech Group of the German Bio Pharmaceutical Industry Organization. He is also accredited as Qualified Person (relevant for the manufacturing of pharmaceutical products). He holds a PhD in chemistry and a MD PhD degree in medicine from the University of Bonn.

All documentation relating to this meeting will be available on Pharming's website as of October 17, 2006.

Background on Pharming Group NV

Pharming Group NV is developing innovative protein products for the treatment of genetic disorders, specialty products for surgical indications, intermediates for various applications and food products. Pharming has two products in late stage development - Rhucin® (recombinant human C1 inhibitor) for hereditary angioedema (under review by EMEA) and human lactoferrin for use in functional foods (GRAS notification under review by US FDA). The advanced technologies of the Company include innovative platforms for the production of protein therapeutics, as well as technology and processes for the purification and formulation of these products. Additional information is available on the Pharming website, http://www.pharming.com.

This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements. The press release also appears in Dutch. In the event of any inconsistency, the English version will prevail over the Dutch version.



Copyright © Hugin ASA 2006. All rights reserved.

Contact Information

  • Contact:

    Carina Hamaker (NL)
    Investor Voice
    T: +31 (0)6 537 49959
    T: +31 (0)71 524 7431

    Samir Singh (US)
    Pharming Group NV
    T: +1 908 720 6224
    T: +1 800 333 1476